Insights

  • Home
  • Insights
  • The Coronavirus Crisis: The Impact of Federal Liability Immunity, Waivers, and Guidance on Health Care Providers

Share

Coronavirus_Crisis_Impact_on_Health_Care_Provider

The Coronavirus Crisis: The Impact of Federal Liability Immunity, Waivers, and Guidance on Health Care Providers

March 19, 2020 White Paper

As novel coronavirus (COVID-19) cases are identified daily, the federal government, through the Department of Health and Human Services and the Centers for Medicare & Medicaid Services, continues to address the pandemic through various measures that affect health care providers.  

Recent federal government agency actions in response to COVID-19 include providing liability immunity for activities related to medical countermeasures against COVID-19, issuing specific 1135 waivers of certain federal regulations to provide additional flexibility to health care providers, providing guidance to health care providers on COVID-19 response efforts through state survey agency memoranda, updating available frequently asked questions related to COVID-19, developing new reimbursement codes for COVID-19 laboratory testing, and suspending many non-emergency CMS surveys to focus facility inspection resources on immediate jeopardy and complaints related to infection control and other serious health and safety threats.

Read the full White Paper.

Insights by Jones Day should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request permission to reprint or reuse any of our Insights, please use our “Contact Us” form, which can be found on our website at www.jonesday.com. This Insight is not intended to create, and neither publication nor receipt of it constitutes, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.
You May Also Be Interested In

January 03, 2025 Newsletters

EU Geopolitical Risk Update – Key Policy & Regulatory Developments No. 118

December 30, 2024 Commentary

FDA's Digital Health Advisory Committee Discusses Total Product Lifecycle Considerations for GenAI-Enabled Devices

December 27, 2024 Alert

FDA's Final Guidance Provides Practical Approach for AI-Enabled Devices Implementing Post-Market Modifications

December 16, 2024 Newsletters

Vital Signs: Digital Health Law Update | Fall-Winter 2024

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.